Having trouble viewing this email? View in your browser. | ||||||||||||||||
SHIONOGI SYMPOSIUM ECCMID 2021
Taking a look inside the Trojan horse You are invited to join Shionogi for We aim to update you on the management of patients Recent trends in the epidemiology and treatment of extensively drug-resistant pathogens in Europe An introduction to cefiderocol as the most recently approved antibiotic in this therapy area Microbiological and clinical evidence supporting cefiderocol from Shionogi´s clinical development program A panel discussion on real-world clinical experience of cefiderocol use
Welcome and introduction Prof. Robert Krause Prof. Emil Lesho The evolving landscape of
Prof. Marco Falcone Cefiderocol:
Prof. Stefania Stefani APEKS & CREDIBLE-CR:
Prof. Ricard Ferrer Q&A session
With presenters
Expert panel:
Prof. Prof. Prof. University Hospital Basel, Basel, Switzerland Q&A session
With the panel
Close
Veeva ID (CH): PP-CH--0007 Fetcroja summary of product characteristics You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here. |